TScan Therapeutics, Inc. Share Price
NASDAQ: TCRX | Micro CapTScan Therapeutics, Inc. Stock Performance
Open $0.75 | Prev. Close $0.76 | Circuit Range N/A |
Day Range $0.75 - $0.76 | Year Range $0.72 - $2.56 | Volume 10,783 |
Average Traded $0.75 |
TScan Therapeutics, Inc. Share Price Today
As of 31 August 2026, TScan Therapeutics, Inc.'s share price is $0.75. The stock opened at $0.75, compared to its previous close of $0.76. During today's trading session, TScan Therapeutics, Inc.'s share price traded between $0.75 and $0.76, with an average price of $0.75. Over the past 52 weeks, the stock has recorded a high of $2.56 and a low of $0.72. In terms of performance, TScan Therapeutics, Inc.'s share price has declined by 29.30% over the last six months and is down 58.17% on a year-on-year basis.
TScan Therapeutics, Inc. Share Price Chart
TScan Therapeutics, Inc. Stock Fundamentals & Key Indicators
Market Cap $97.72M | PE Ratio (TTM) -0.75 | Dividend Yield N/A |
EPS (TTM) $-1.00 | Revenue (TTM) $10.32M | Return On Equity (TTM) -105.40% |
Profit Margin -1256.81% | Debt to Equity 0.15 | Quarterly Earnings Growth YoY -19.48% |
TScan Therapeutics, Inc. Quarterly Profit & Loss
All figures in USD
TScan Therapeutics, Inc. Annual Profit & Loss
All figures in USD
About TScan Therapeutics, Inc.
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also advanced TS-102 into IND-enabling activities. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors. It has collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
TScan Therapeutics, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $0.75 | $0.76 | +1.34% |
Jul 2026 | $1.02 | $0.75 | -23.88% |
Jun 2026 | $1.07 | $0.98 | -9.68% |
May 2026 | $1.14 | $1.08 | -7.26% |
Apr 2026 | $1.04 | $1.17 | +16.53% |
Mar 2026 | $1.07 | $1.00 | -5.73% |
Feb 2026 | $1.04 | $1.06 | +3.90% |
Jan 2026 | $1.00 | $1.02 | +3.02% |
Dec 2025 | $1.11 | $0.99 | -11.16% |
Nov 2025 | $1.44 | $1.12 | -42.27% |
Oct 2025 | $1.83 | $1.94 | +9.60% |
Sep 2025 | $1.85 | $1.77 | -1.67% |
TCRX Share Price FAQs
What is TScan Therapeutics, Inc. share price today?
What is the 52 week high and 52 week low of TScan Therapeutics, Inc. stock?
What is TCRX's market capitalisation today?
What is TCRX's net income for the last quarter?
What is the 5 year returns of TCRX?
What is the high & low stock price of TCRX today?
Can I buy TCRX shares in India?